The estimated Net Worth of Gisela Schwab is at least $19.5 Milion dollars as of 26 July 2021. Gisela Schwab owns over 40,000 units of Exelixis Inc stock worth over $18,350,147 and over the last 18 years he sold EXEL stock worth over $67,795. In addition, he makes $1,128,480 as President - Product Development and Medical Affairs a Chief Medical Officer at Exelixis Inc.
Sign up
Gisela Schwab EXEL stock SEC Form 4 insiders trading
Gisela has made over 59 trades of the Exelixis Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of EXEL stock worth $168,000 on 26 July 2021.
The largest trade he's ever made was exercising 132,662 units of Exelixis Inc stock on 31 August 2016 worth over $1,290,801. On average, Gisela trades about 24,562 units every 49 days since 2006. As of 26 July 2021 he still owns at least 689,078 units of Exelixis Inc stock.
You can see the complete history of Gisela Schwab stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gisela Schwab biography
Dr. Gisela M. Schwab M.D. serves as President - Product Development and Medical Affairs, Chief Medical Officer of the Company. Gisela M. Schwab, M.D., has served as President, Product Development and Medical Affairs and Chief Medical Officer since February 2016. Previously she served as Executive Vice President and Chief Medical Officer from January 2008 to February 2016 and as Senior Vice President and Chief Medical Officer from September 2006 to January 2008. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development, at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. From August 2011 through July 2014, Dr. Schwab served as a member of the board of directors of Topotarget A/S, a publicly held biopharmaceutical company. She has served as a member of the board of directors of Cellerant Therapeutics, Inc. a privately held biopharmaceutical company since June 2012, as a member of the board of directors of Genocea Biosciences, Inc., a publicly held biopharmaceutical company, since February 2020, and as a member of the board of directors of Nordic Nanovector A.S. (Nordic), a Norwegian biotechnology company, since March 2015. Dr. Schwab will be stepping down from the Nordic board of directors at Nordic’s next Annual General Meeting in April 2020. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology.
What is the salary of Gisela Schwab?
As the President - Product Development and Medical Affairs a Chief Medical Officer of Exelixis Inc, the total compensation of Gisela Schwab at Exelixis Inc is $1,128,480. There are 2 executives at Exelixis Inc getting paid more, with Dr. Michael M. Morrissey having the highest compensation of $2,349,812.
How old is Gisela Schwab?
Gisela Schwab is 63, he's been the President - Product Development and Medical Affairs a Chief Medical Officer of Exelixis Inc since 2016. There are 9 older and 12 younger executives at Exelixis Inc. The oldest executive at Exelixis Inc is Vincent Marchesi, 84, who is the Independent Director.
What's Gisela Schwab's mailing address?
Gisela's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Insiders trading at Exelixis Inc
Over the last 23 years, insiders at Exelixis Inc have traded over $82,392,913 worth of Exelixis Inc stock and bought 1,847,609 units worth $19,175,184 . The most active insiders traders include Jean Francois Formela, Michael Morrissey a Stelios Papadopoulos. On average, Exelixis Inc executives and independent directors trade stock every 12 days with the average trade being worth of $898,709. The most recent stock trade was executed by Jeffrey Hessekiel on 26 August 2024, trading 20,000 units of EXEL stock currently worth $488,200.
What does Exelixis Inc do?
exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.
What does Exelixis Inc's logo look like?
Complete history of Gisela Schwab stock trades at Exelixis Inc a Genocea Biosciences Inc
Exelixis Inc executives and stock owners
Exelixis Inc executives and other stock owners filed with the SEC include:
-
Dr. Michael M. Morrissey,
CEO, Pres & Director -
Michael Morrissey,
President, Chief Executive Officer, Director -
Gisela Schwab,
President - Product Development and Medical Affairs, Chief Medical Officer -
Christopher J. Senner,
Exec. VP & CFO -
Christopher Senner,
Chief Financial Officer, Executive Vice President -
Jeffrey J. Hessekiel,
Exec. VP, Gen. Counsel & Sec. -
Jeffrey Hessekiel,
Executive Vice President, General Counsel -
Patrick J. Haley M.B.A., MBA,
Exec. VP of Commercial -
Peter Lamb,
Executive Vice President - Scientific Strategy, Chief Scientific Officer -
Stelios Papadopoulos,
Independent Chairman of the Board, Co-Founder -
Charles Cohen,
Independent Director -
Jack Wyszomierski,
Independent Director -
George Poste,
Independent Director -
Vincent Marchesi,
Independent Director -
Julie Smith,
Independent Director -
Alan Garber,
Independent Director -
Maria Freire,
Independent Director -
Carl Feldbaum,
Independent Director -
Lance Willsey,
Independent Director -
Dr. Stelios Papadopoulos Ph.D.,
Co-Founder & Independent Chairman -
Patrick Haley,
Executive Vice President - Commercial -
Laura Dillard,
Exec. VP of HR -
Gregg Bernier,
VP of Marketing -
Susan T. Hubbard,
Exec. VP of Public Affairs & Investor Relations -
Dr. Peter Lamb,
Exec. VP of Scientific Strategy & Chief Scientific Officer -
Dr. Dana T. Aftab,
Exec. VP of Bus. Operations -
George A Scangos,
Director -
Dana Aftab,
CSO/EVP Disc & Trans Research -
Mary C Beckerle,
Director -
David Edward Caligan Partne...,
-
Sue Gail Eckhardt,
Director -
Bob Oliver,
Director -
Tomas J. Heyman,
Director -
Jacqueline Wright,
Director -
Pamela A Simonton,
VP, Corp Tech Development -
Frank Karbe,
Senior VP & CFO -
Deborah Burke,
SVP & Chief Financial Officer -
Jeffrey Latts,
Sr VP, Chief Medical Officer -
Peter Stalder,
Director -
Jason S Fisherman,
Director -
Kristine M Ball,
Controller & Interim CFO -
Frank Mccormick,
Director -
Steven P James,
Sr VP, Commercial Ops -
Jane M Green,
VP, Corp Communications -
Glen Y Sato,
CFO Sec and General Counsel -
Jean Francois Formela,
Director -
Lupe M Rivera,
VP, HUMAN RESOURCES -
Frances K Heller,
EVP, Business Development -
Ian D Malcolm,
VP, STRATEGIC MARKETING -
Christoph Pereira,
VP, Legal Affairs & Secretary -
J. Scott Garland,
EVP & Chief Commerical Officer -
Gregory Plowman,
Sr VP, Research -
Geoffrey M Duyk,
Pres R&D & Chief Sc Off -
Vicki L Goodman,
EVP, Prod Dev & Med Aff &CMO -
Amy C. Peterson,
EVP Prod Dev & Med Aff & CMO